WO2013109226A1 - Pharmaceutical tablet formulations comprising cefuroxime - Google Patents

Pharmaceutical tablet formulations comprising cefuroxime Download PDF

Info

Publication number
WO2013109226A1
WO2013109226A1 PCT/TR2013/000039 TR2013000039W WO2013109226A1 WO 2013109226 A1 WO2013109226 A1 WO 2013109226A1 TR 2013000039 W TR2013000039 W TR 2013000039W WO 2013109226 A1 WO2013109226 A1 WO 2013109226A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
tablet formulation
pharmaceutical
formulation according
cefuroxime axetil
Prior art date
Application number
PCT/TR2013/000039
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013109226A1 publication Critical patent/WO2013109226A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to pharmaceutical tablet formulations comprising cefuroxime axetil to be used in the treatment of upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as cystitis and urethritis; and skin and soft tissue infections such as furuncle, pyoderma, impetigo; gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.
  • upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis
  • lower respiratory tract infections such as cystitis and urethritis
  • skin and soft tissue infections such as furuncle, pyoderma, impetigo; gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.
  • Cefuroxime axetil was first disclosed with the patent application numbered US3974153. In said document, cefuroxime axetil was indicated to be effective for use in treatment of upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as cystitis and urethritis; and skin and soft tissue infections such as furuncle, pyoderma, impetigo; in the treatment of gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.
  • upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis
  • lower respiratory tract infections such as cystitis and urethritis
  • skin and soft tissue infections such as furuncle, pyoderma, impetigo
  • Cefuroxime axetil physically appears in the forms of suspension and 100-5000 mg tablets on the market.
  • Tablet hardness provides resistance of tablets to storage, transport, coating and erosion- breakage before usage. Erosion, friability or breakage of tablets is often caused by low hardness and this case leads to the loss of active agent and changes the amount of dose taken. Another consequence of low hardness is the erosion of tablet surface during coating process and dosage forms which have uneven surfaces leading to variable amounts of active agent in the final product while producing coated tablet forms.
  • dispersibility and solubility of a tablet is also dependent on its hardness. Tablets that are too hard do not disperse or dissolve adequately; in this case, bioavailability of said dosage forms will decrease and therefore the time for desired biological response to occur will extend. The same case is also true for all types of tablets such as effervescent, film- coated, soluble, extended-release, modified-release, delayed-release tablets etc.
  • tablet hardness is influenced by many parameters such as the types of active agents and excipients used, particle sizes thereof, flowability of the powder or granules prepared for tablet compression. The particle size of the active agent therefore gains importance considering weight uniformity of the formulation. The homogeneity of the composition can be lost if the proper flow is not provided.
  • the particle size of the active agent and the tablet hardness should be in a specific range to
  • the tablet formulations of the present invention comprising cefuroxime axetil and at least one pharmaceutically acceptable excipient wherein tablet hardness value is between 3 kP and 50 kP, preferably 4 kP and 40 kP, more preferably 5 kP and 30 kP and the dlOO value of cefuroxime axetil is in the range of 1500-200 ⁇ , preferably 1300-250 ⁇ , more preferably 1000-300.
  • tablet formulations of the present invention comprise cefuroxime axetil as active agent and at least one pharmaceutically acceptable excipient is characterized in that the ⁇ tablet hardness value is between 3 kP and 50 kP and
  • tablet formulations of the present invention comprise cefuroxime axetil as active agent and at least one pharmaceutically acceptable excipient is characterized in that the • tablet hardness value is between 4 kP and 40 kP and
  • tablet hardness value is between 5 kP and 30 kP
  • tablette used throughout the text refers to tablet types such as tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet.
  • the pharmaceutical formulation of the present invention is preferably in the form of film- coated tablet.
  • the term "dlOO value” denotes the value of the particle size up to which cumulatively 100% of the particles in the particle size distribution were found to lie.
  • the pharmaceutical formulations of the present invention comprise at least one pharmaceutically acceptable excipient selected from the group comprising disintegrant, diluent, lubricant, glidant, binder.
  • the diluent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
  • the lubricant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polythylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
  • the glidant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising tribasic calcium phosphate, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc or combinations thereof.
  • the binder that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, maltodextrin, methyl cellulose, povidone, starch or combinations thereof.
  • cefuroxime axetil tablet formulations Another problem observed in cefuroxime axetil tablet formulations is low dissolution of the tablet forms due to the high hardness.
  • the inventors have conducted studies on finding the desired formulation in order to have the required hardness of the tablet enough to resist the manufacturing process but also soluble enough to provide the necessary bioavailability for the patients. Based on these studies, it is observed that the ratio of cefuroxime axetil: disintegrant should be in the range of 10: 1 to 1 :2, preferably 8:1 to 1 :1 by weight.
  • a characteristic feature of the present invention is that the ratio of cefuroxime axetil: disintegrant is in the range of 10: 1 to 1 :2, preferably 8: 1 to 1 : 1 by weight.
  • a further need of the tablet formulations comprising cefuroxime axetil is the use of excipients in required amounts such that the required tablet hardness and dissolution rate are attained. Accordingly, it is observed that the cefuroxime axetil tablets have these desired physical properties when the ratio of disintegrant to diluent is in the range of 7:1 to 1 :7, preferably 5: 1 to 1 :5 by weight.
  • the ratio of disintegrant to diluent is in the range of 7:1 to 1 :7, preferably 5:1 to 1 :5 by weight.
  • the pharmaceutical formulations of the invention comprising cefuroxime axetil as active agent comprise cefuroxime axetil in the range of 25 to 90%, preferably in the range of 40 to 80%, more preferably in the range of 45 to 75% by weight.
  • Said tablet formulations can optionally be treated with film-coating agents, for instance sugar- based coating agents, water-soluble film-coating agents, enteric coating agents, coating agents prepared to provide various release properties (such as fast release, slow release, controlled release) or coating compositions comprising any combination thereof.
  • film-coating agents for instance sugar-based coating agents, water-soluble film-coating agents, enteric coating agents, coating agents prepared to provide various release properties (such as fast release, slow release, controlled release) or coating compositions comprising any combination thereof.
  • sugar-based coating agent saccharose can be used on its own or optionally with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatin, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
  • the water-soluble film-coating agents can be selected from cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan; or combinations thereof.
  • cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose
  • synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan; or combinations thereof.
  • the enteric coating agents can be selected from cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S; and natural substances such as shellac; or combinations thereof.
  • cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate
  • acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S
  • natural substances such as shellac; or combinations thereof.
  • film coating agents can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin and/or combinations thereof.
  • a film coating agent branded as Opadry® can be used in the present invention.
  • the preparation method of the formulations of the invention comprises formulating the active agent with an appropriate excipient composition and compressing said formulation in the form of tablets under an appropriate compression force.
  • a characteristic of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent, at least one pharmaceutically acceptable excipient and the tablet compression force used for compressing said formulations in the form of tablets is between 3 kN and 50 kN.
  • a characteristic feature of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent, at least one pharmaceutically acceptable excipient and the tablet compression force used for compressing said formulations in the form of tablets is between 4 kN and 45 kN.
  • tablet formulations of the present invention comprise cefuroxime axetil as active agent, at least one pharmaceutically acceptable excipient and the tablet compression power used for compressing said formulations in the form of tablets is between 5 kN and 40 kN.
  • the tablet formulations of the invention can be produced in accordance with any of the production methods given below; 1. Mixing disintegrant with at least one other excipient,
  • the pharmaceutical composition of the invention can be used for upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as pyelonephritis, cystitis and urethritis; skin and soft tissue infections such as furuncle, pyoderma, impetigo; in the prophylaxis and treatment of gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.
  • upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis
  • lower respiratory tract infections such as pyelonephritis, cystitis and urethritis
  • skin and soft tissue infections such as furuncle, pyoderma, impetigo
  • skin and soft tissue infections such as furuncle, pyoderma, impetigo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical tablet formulations comprising cefuroxime axetil to be used in the treatment of upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as cystitis and urethritis; and skin and soft tissue infections such as furuncle, pyoderma, impetigo; gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.

Description

PHARMACEUTICAL TABLET FORMULATIONS COMPRISING CEFUROXIME
The present invention relates to pharmaceutical tablet formulations comprising cefuroxime axetil to be used in the treatment of upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as cystitis and urethritis; and skin and soft tissue infections such as furuncle, pyoderma, impetigo; gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.
Cefuroxime axetil was first disclosed with the patent application numbered US3974153. In said document, cefuroxime axetil was indicated to be effective for use in treatment of upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as cystitis and urethritis; and skin and soft tissue infections such as furuncle, pyoderma, impetigo; in the treatment of gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.
Cefuroxime axetil physically appears in the forms of suspension and 100-5000 mg tablets on the market.
In the sense of pharmaceutical technology, physical properties of dosage form for every type of tablet dosage form are directly related to durability in storage conditions; dissolution and bioavailability of the dosage form obtained.
One of the physical properties important in pharmaceutical formulations is tablet hardness. Tablet hardness provides resistance of tablets to storage, transport, coating and erosion- breakage before usage. Erosion, friability or breakage of tablets is often caused by low hardness and this case leads to the loss of active agent and changes the amount of dose taken. Another consequence of low hardness is the erosion of tablet surface during coating process and dosage forms which have uneven surfaces leading to variable amounts of active agent in the final product while producing coated tablet forms.
On the other hand, dispersibility and solubility of a tablet is also dependent on its hardness. Tablets that are too hard do not disperse or dissolve adequately; in this case, bioavailability of said dosage forms will decrease and therefore the time for desired biological response to occur will extend. The same case is also true for all types of tablets such as effervescent, film- coated, soluble, extended-release, modified-release, delayed-release tablets etc. Furthermore, tablet hardness is influenced by many parameters such as the types of active agents and excipients used, particle sizes thereof, flowability of the powder or granules prepared for tablet compression. The particle size of the active agent therefore gains importance considering weight uniformity of the formulation. The homogeneity of the composition can be lost if the proper flow is not provided. This case leads to the loss of the weight uniformity and variations of the drug dose taken in each tablet. Consequently, the efficiency of the treatment decreases because of weight and content uniformity loss observed in the dosage forms obtained. When all of these parameters are considered, the particle size of the active agent and the tablet hardness should be in a specific range to
• provide good flow properties of the formulation,
• ensure the amount of the drug taken in each dose and eventually
• increase the bioavailability of the drug by being dissolved adequately. As a result of the development studies conducted on pharmaceutical tablet formulations, the inventors have found that the required physical parameters such as hardness and solubility are achieved when the tablet formulations of the present invention comprising cefuroxime axetil and at least one pharmaceutically acceptable excipient wherein tablet hardness value is between 3 kP and 50 kP, preferably 4 kP and 40 kP, more preferably 5 kP and 30 kP and the dlOO value of cefuroxime axetil is in the range of 1500-200 μιη, preferably 1300-250 μηι, more preferably 1000-300.
According to this, another characteristic of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent and at least one pharmaceutically acceptable excipient is characterized in that the · tablet hardness value is between 3 kP and 50 kP and
• dlOO value of cefuroxime axetil is in the range of 1500-200 μηι.
Another characteristic of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent and at least one pharmaceutically acceptable excipient is characterized in that the • tablet hardness value is between 4 kP and 40 kP and
• dl 00 value of cefuroxime axetil is in the range of 1300-250 μηι.
A further characteristic of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent and at least one pharmaceutically acceptable excipient and are characterized in that the
• tablet hardness value is between 5 kP and 30 kP and
• dlOO value of cefuroxime axetil is in the range of 1000-300 μηι.
The term "tablet" used throughout the text refers to tablet types such as tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet.
The pharmaceutical formulation of the present invention is preferably in the form of film- coated tablet.
The term "dlOO value" denotes the value of the particle size up to which cumulatively 100% of the particles in the particle size distribution were found to lie. The pharmaceutical formulations of the present invention comprise at least one pharmaceutically acceptable excipient selected from the group comprising disintegrant, diluent, lubricant, glidant, binder.
The diluent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
The lubricant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polythylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof. The glidant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising tribasic calcium phosphate, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc or combinations thereof.
The binder that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, maltodextrin, methyl cellulose, povidone, starch or combinations thereof.
Another problem observed in cefuroxime axetil tablet formulations is low dissolution of the tablet forms due to the high hardness. The inventors have conducted studies on finding the desired formulation in order to have the required hardness of the tablet enough to resist the manufacturing process but also soluble enough to provide the necessary bioavailability for the patients. Based on these studies, it is observed that the ratio of cefuroxime axetil: disintegrant should be in the range of 10: 1 to 1 :2, preferably 8:1 to 1 :1 by weight. In this regard, a characteristic feature of the present invention is that the ratio of cefuroxime axetil: disintegrant is in the range of 10: 1 to 1 :2, preferably 8: 1 to 1 : 1 by weight.
A further need of the tablet formulations comprising cefuroxime axetil is the use of excipients in required amounts such that the required tablet hardness and dissolution rate are attained. Accordingly, it is observed that the cefuroxime axetil tablets have these desired physical properties when the ratio of disintegrant to diluent is in the range of 7:1 to 1 :7, preferably 5: 1 to 1 :5 by weight.
Another characteristic of the present invention is that the ratio of disintegrant to diluent is in the range of 7:1 to 1 :7, preferably 5:1 to 1 :5 by weight.
The pharmaceutical formulations of the invention comprising cefuroxime axetil as active agent comprise cefuroxime axetil in the range of 25 to 90%, preferably in the range of 40 to 80%, more preferably in the range of 45 to 75% by weight.
Said tablet formulations can optionally be treated with film-coating agents, for instance sugar- based coating agents, water-soluble film-coating agents, enteric coating agents, coating agents prepared to provide various release properties (such as fast release, slow release, controlled release) or coating compositions comprising any combination thereof. As sugar-based coating agent, saccharose can be used on its own or optionally with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatin, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
The water-soluble film-coating agents can be selected from cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pullulan; or combinations thereof.
The enteric coating agents can be selected from cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S; and natural substances such as shellac; or combinations thereof.
Other film coating agents can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin and/or combinations thereof. For example, a film coating agent branded as Opadry® can be used in the present invention.
The preparation method of the formulations of the invention comprises formulating the active agent with an appropriate excipient composition and compressing said formulation in the form of tablets under an appropriate compression force. A characteristic of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent, at least one pharmaceutically acceptable excipient and the tablet compression force used for compressing said formulations in the form of tablets is between 3 kN and 50 kN.
A characteristic feature of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent, at least one pharmaceutically acceptable excipient and the tablet compression force used for compressing said formulations in the form of tablets is between 4 kN and 45 kN.
Another characteristic of the tablet formulations of the present invention is that said tablet formulations comprise cefuroxime axetil as active agent, at least one pharmaceutically acceptable excipient and the tablet compression power used for compressing said formulations in the form of tablets is between 5 kN and 40 kN.
The tablet formulations of the invention can be produced in accordance with any of the production methods given below; 1. Mixing disintegrant with at least one other excipient,
2. Adding cefuroxime axetil as active agent forming a first mixture,
3. Adding at least one other excipient to the first mixture,
4. Forming a second mixture with disintegrant and at least one other excipient,
5. Combining these two mixtures and lubricating it with lubricant forming a final mixture,
6. Compressing the final mixture into tablet dosage form,
7. Coating the tablet with a coating solution containing a film-coating agent,
The pharmaceutical composition of the invention can be used for upper respiratory tract infections such as otorhinolaryngological infections, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as pyelonephritis, cystitis and urethritis; skin and soft tissue infections such as furuncle, pyoderma, impetigo; in the prophylaxis and treatment of gonorrhea and lyme diseases caused by gram positive and gram negative bacteria.
The examples below are given to explain the pharmaceutical compositions of the invention and the preparation methods thereof; the scope of the invention cannot be limited to these examples.
EXAMPLE
1. Film-Coated Tablet Formulation
Figure imgf000008_0001
The production method to be applied for the tablet formulations to be prepared according to the formulation given above is as follows;
1. Mixing disintegrant with at least one other excipient,
2. Adding cefuroxime axetil as active agent forming a first mixture,
3. Adding at least one other excipient to the first mixture,
4. Forming a second mixture with disintegrant and at least one other excipient,
5. Combining these two mixtures and lubricating it with lubricant forming a final mixture,
6. Compressing the final mixture into tablet dosage form,
7. Coating the tablet with a coating solution containing a film-coating agent,

Claims

1. A pharmaceutical tablet formulation comprising cefuroxime axetil as active agent with at least one pharmaceutically acceptable excipient, characterized in that
• tablet hardness value of said tablet formulation is between 3 and 50 kP and
• dlOO value of cefuroxime axetil is in the range of 1500-200 μηι.
2. The pharmaceutical tablet formulation according to claim 1, characterized in that tablet hardness value of said tablet formulation is between 4 and 40 kP.
3. The pharmaceutical tablet formulation according to claims 1 and 2, characterized in that tablet hardness value of said tablet formulation is between 5 and 30 kP.
4. The pharmaceutical tablet formulation according to claims 1-3, characterized in that dlOO value of cefuroxime axetil is in the range of 1300-250 μηι.
5. The pharmaceutical tablet formulation according to claims 1-4, characterized in that dlOO value of cefuroxime axetil is in the range of 1000-300 μηι.
6. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that said tablet formulation is in the form of any of tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet dosage forms.
7. The pharmaceutical tablet formulation according to claim 6, characterized in that said tablet formulation is in the form of film-coated tablet.
8. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that at least one pharmaceutically acceptable excipient to be used with cefuroxime axetil is selected from the group comprising disintegrant, diluent, lubricant, glidant, binder.
9. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that the ratio of cefuroxime axetil: disintegrant is in the range of 10:2 to 1 :2 by weight.
10. The pharmaceutical tablet formulation according to claim 9, characterized in that the ratio of cefuroxime axetil: disintegrant is in the range of 8:1 to 1 :1 by weight.
11. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that the ratio of disintegrant to diluent is in the range of 7:1 to 1 :7 by weight.
12. The pharmaceutical tablet formulation according to claim 11, characterized in that the ratio of disintegrant to diluent is in the range of 5:1 to 1 :5 by weight.
13. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that said tablet formulation comprises cefuroxime axetil in the range of 25-90% by weight.
14. The pharmaceutical tablet formulation according to claim 13, characterized in that said tablet formulation comprises cefuroxime axetil in the range of 40-80% by weight.
15. The pharmaceutical tablet formulation according to claim 14, characterized in that said tablet formulation comprises cefuroxime axetil in the range of 45-75% by weight.
16. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that the tablet compression force used for tablet compression is between 3 and 50 kN.
17. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that the tablet compression force used for tablet compression is between 4 and 45 kN.
18. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that the tablet compression power used for tablet compression is between 5 and 40 kN.
PCT/TR2013/000039 2012-01-18 2013-01-18 Pharmaceutical tablet formulations comprising cefuroxime WO2013109226A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201200595 2012-01-18
TR2012/00595 2012-01-18

Publications (1)

Publication Number Publication Date
WO2013109226A1 true WO2013109226A1 (en) 2013-07-25

Family

ID=47913528

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2013/000018 WO2013109206A1 (en) 2012-01-18 2013-01-16 Tablet formulations comprising cefuroxime
PCT/TR2013/000039 WO2013109226A1 (en) 2012-01-18 2013-01-18 Pharmaceutical tablet formulations comprising cefuroxime

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000018 WO2013109206A1 (en) 2012-01-18 2013-01-16 Tablet formulations comprising cefuroxime

Country Status (1)

Country Link
WO (2) WO2013109206A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103505434A (en) * 2013-09-16 2014-01-15 江苏正大清江制药有限公司 Cefuroxime axetil tablet and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974153A (en) 1971-05-14 1976-08-10 Glaxo Laboratories Limited 7-Hydrocarbonoxy imino-acetamido-3-carbamoyloxy methylceph-3-em-4 carboxylic acids
EP1342470A1 (en) * 2002-03-04 2003-09-10 Pharmathen S.A. Fast release cefuroxime axetil compositions
US20050079213A1 (en) * 2003-06-06 2005-04-14 Unilab Pharmatech Ltd Pharmaceutical compositions
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
EP2510922A1 (en) * 2011-04-14 2012-10-17 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Manufacturing process for tablet formulations comprising cefuroxime

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100552567B1 (en) * 2003-08-23 2006-02-15 한국유나이티드제약 주식회사 Formulation of stable for moisture absorption and quickly dissolved tablet containing cefuroxime axetil and it's manufacturing process

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974153A (en) 1971-05-14 1976-08-10 Glaxo Laboratories Limited 7-Hydrocarbonoxy imino-acetamido-3-carbamoyloxy methylceph-3-em-4 carboxylic acids
EP1342470A1 (en) * 2002-03-04 2003-09-10 Pharmathen S.A. Fast release cefuroxime axetil compositions
US20050079213A1 (en) * 2003-06-06 2005-04-14 Unilab Pharmatech Ltd Pharmaceutical compositions
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
EP2510922A1 (en) * 2011-04-14 2012-10-17 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Manufacturing process for tablet formulations comprising cefuroxime

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103505434A (en) * 2013-09-16 2014-01-15 江苏正大清江制药有限公司 Cefuroxime axetil tablet and preparation method thereof

Also Published As

Publication number Publication date
WO2013109206A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
CN107530348B (en) Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
CN106943355B (en) Pharmaceutical composition
EP2854759B1 (en) Dosage forms comprising apixaban and matrix former
EP2740471B1 (en) Oral pharmaceutical composition comprising dabigatran etexilate
JP2010520891A (en) Nevirapine sustained release formulation
TW202038917A (en) Extended release formulation containing tofacitinib or pharmaceutically acceptable salts thereof and preparation method for the same
JP5208729B2 (en) Method for producing sustained-release tablets
EP2620140A1 (en) Crizotinib containing compositions
KR20200088382A (en) Controlled release formulations
JP2017523149A (en) Edoxaban pharmaceutical composition
WO2013109227A1 (en) Pharmaceutical compositions comprising ceftibuten
WO2013100880A1 (en) Formulations comprising cefuroxime
JP2013043834A (en) Elution improving solid preparation
WO2013109226A1 (en) Pharmaceutical tablet formulations comprising cefuroxime
WO2010120963A1 (en) Tablet formulation for p38 inhibitor and method
WO2017037645A1 (en) Stable pharmaceutical formulations of teriflunomide
WO2013109205A1 (en) Pharmaceutical tablet formulations comprising cefetamet
RU2367438C2 (en) Controlled release trimetazidine matrix tablet
Kumar et al. Formulation and evaluation of matrix tablets of acarbose
JP2021518422A (en) Pharmaceutical composition containing lenalidomide
EP2875807B1 (en) Tablet formulation of colesevelam
WO2013109203A1 (en) Tablet formulations comprising cefditoren pivoxil
WO2013109229A1 (en) Tablet formulations comprising cefixime as active agent
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
EP3545951A1 (en) Oral tablet composition comprising dexlansoprazole, oral tablet comprising same and method for manufacturing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13713586

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13713586

Country of ref document: EP

Kind code of ref document: A1